Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

DOI PDF 被引用文献5件
  • Steven M. Devine
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Ron Hoffman
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Amit Verma
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Rajul Shah
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Basil A. Bradlow
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Wendy Stock
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Vera Maynard
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Ellen Jessop
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • David Peace
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Marianne Huml
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Deana Thomason
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Yi-Hsiang Chen
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
  • Koen van Besien
    From the Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL

抄録

<jats:title>Abstract</jats:title> <jats:p>Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m2 intravenously daily for 5 days) and melphalan (70 mg/m2 intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.</jats:p>

収録刊行物

  • Blood

    Blood 99 (6), 2255-2258, 2002-03-15

    American Society of Hematology

被引用文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ